aoc 1020
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Apr 4, 2023 (NCT05747924)
Timeline
Indications
Mechanism of action
- Double homeobox protein 4INHIBITOR
inhibitor - DUX4
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07038200 | Phase 3 | Jun 10, 2025 | Avidity Biosciences, Inc. |
| NCT06547216 | Phase 2 | Jul 25, 2024 | Avidity Biosciences, Inc. |
| NCT05747924 | Phase 1/Phase 2 (Phase 2) | Apr 4, 2023 | Avidity Biosciences, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Avidity Biosciences, Inc. | For profit | 3 | 3 | 2 | 2023 |
1 organizations
Page 1 / 1